Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
In a report released today, from Mizuho Securities maintained a Buy rating on Crispr Therapeutics AG, with a price target of $85.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In addition to Mizuho Securities, Crispr Therapeutics AG also received a Buy from Piper Sandler’s Edward Tenthoff in a report issued on March 17. However, on the same day, TipRanks – xAI reiterated a Hold rating on Crispr Therapeutics AG (NASDAQ: CRSP).
Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $864 thousand and a GAAP net loss of $130.61 million. In comparison, last year the company earned a revenue of $35 million and had a GAAP net loss of $37.31 million
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year. Most recently, in January 2026, Naimish Patel, the CMO of CRSP bought 1,508.00 shares for a total of $49,703.68.
Read More on CRSP:
Disclaimer & DisclosureReport an Issue
- Cathie Wood’s ARK Invest Dumps $2.1M Worth of META Shares; Stock Sinks
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler
- Crispr Therapeutics Completes $600 Million Convertible Notes Offering
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS
